Advertisement

Topics

Novartis’ CAR-T Therapy Kymriah Receives FDA Approval to Treat R/R Patients with Large B-Cell Lymphoma

11:31 EDT 3 May 2018 | Speciality Pharma Journal

Basel, May 1, 2018 – Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell …

Original Article: Novartis’ CAR-T Therapy Kymriah Receives FDA Approval to Treat R/R Patients with Large B-Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Novartis’ CAR-T Therapy Kymriah Receives FDA Approval to Treat R/R Patients with Large B-Cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...